Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБУ «Федеральный центр сердечно-сосудистой хирургии» МЗ РФ, г. Пенза 440071 Россия, г. Пенза, ул. Стасова 6
Evaluation of safety and efficacy of new domestic coronary stents «Medeng»
Список исп. литературыСкрыть список 1. Hoffmann R., Mintz G. Coronary in-stent restenosis – predictors, treatment and prevention. European Heart Journal 2000; 21: 1739–1749. 2. Ben-Dor I., Waksman R., Pichard A.et al. The Current Role of Bare-Metal Stents. Cardiac interv. 2011; 1: 57–62. 3. Kastrati A., Schömig A., Elezi S., Dirschinger J et al. Prognostic Value of the Modified American College of Cardiology/American Heart Association Stenosis Morphology Classification for Long-Term Angiographic and Clinical Outcome After Coronary Stent Placement. Circulation. 1999; 100: 1285–1290. 4. Lagerqvist B., James S., Stenestrand U., Lindbck J., Nilsson T., Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N. Engl. J. Med. 2007; 356: 1009–1019 5. Sketch M., Ball M., Rutherford B., Popma J.J., Russell C., Kereiakes D.J. Driver Investigators. Evaluation of the Medtronic (Driver) cobalt-chromium alloy coronary stent system. Am. J. Cardiol. 2005;95:8–12. 6. Farb A., et al., Pathology of acute and chronic coronary stenting in humans. Circulation. 1999; 99(1): p. 44–52. 7. Sarno G., et al. Lower risk of stent thrombosis and restenosis with unrestricted use of newgeneration drug-eluting stents: a report from the nation wide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur. Heart J. 2012; 33(5): p. 606–13. 8. Camenzind E., Steg P., Wijns W. Stent thrombosis late after implantation of First-generation drug-eluting stents: a cause for concern. Circulation. 2007; 115: 1440–155. 9. Lagerqvist B., James S., Stenestrand U., Lindbck J., Nilsson T., Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N.Engl. J. Med. 2007; 356: 1009–1019. 10. Bavry A., Kumbhani D., Helton T., et al. Late thrombosis of drug-eluting stents: a metaanalysis of randomized clinical trials. Am. J. Med. 2006;119:1056–1061. 11. Morice M., Urban P., Greene S., Schuler G., Chevalier B. Why are we still using Coronary Bare-Metal Stents? JACC. 2013;61;1122–3. 12. Steinberg D., Mishra S., Javaid A., et al. Comparison of effectiveness of bare metal stents versus drug-eluting stents in large (³3.5 mm) coronary arteries. Am. J. Cardiol. 2007;99:599–602. 13. Kim T., Nam C., Hur S., et al. Two-year clinical outcomes after large coronary stent (4.0 mm) placement: comparison of bare-metal stent versus drug-eluting stent. Clin. Cardiol. 2010;33:620–625. 14. Bocksch W., Pomar F., Dziarmaga M., Tresukosol D et al. Clinical safety and efficacy of a novel thin-strut cobalt-chromium coronary stent system: results of the real world Coroflex Blue Registry. Catheter Cardiovasc. Interv. 2010 Jan 1;75(1):78–85. 15. Cassese S., Byrne R., Tada T. et al. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart.2014 Jan;100(2):153–9. 16. Serruys P., Morice M., Kappetein A., et al. SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N. Engl. J. Med. 2009;360:961–972.